Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Substantial Residual Cardiovascular Risk After Intensive Statin Therapy Post-ACS

47-Year-Old Man: Recent ACS

47-Year-Old Man: Recent ACS (cont)

Risk of Major CV Event by LDL and Non-HDL-C Categories

47-Year-Old Man: Treatment Decision

47-Year-Old Man: Treatment Decision

AIM-HIGH: Baseline Lipids (mg/dL)

47-Year-Old Man: Treatment Decision

47-Year-Old Man: Treatment Decision

SANDS: Effect of Aggressive vs Standard Lipid Goals on CIMT

47-Year-Old Man: Treatment Decision

GISSI-Prevenzione: Effect of n-3 PUFAs 1 g/d on CV Outcomes

PROVE-IT: Effect of Intensive vs Standard Therapy on Change in LDL-C at 4 Months

Non-HDL-C vs LDL-C: Predicting All-Cause Mortality

55-Year-Old Woman With T2DM

55-Year-Old Woman (cont)

55-Year-Old Woman With T2DM

ADVENT: Niacin and Blood Glucose in T2DM

55-Year-Old Woman With T2DM

FIELD: Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy

55-Year-Old Woman With T2DM

55-Year-Old Woman With T2DM

COMBOS: Change in Lipid Parameters

Program Summary

Abbreviations

Abbreviations

Abbreviations